Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axsome Therapeutics Inc.

www.axsome.com

Latest From Axsome Therapeutics Inc.

Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway

Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.

Deals M & A

Finance Watch: Forma Raises $100m In Quest To Become A Sickle Cell Leader

The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA. 

Financing Business Strategies

Axsome Soars After Depression Trial Success

Axsome is set to file for approval in the second half of 2020.

Clinical Trials Research & Development

Phase III Study Failure Clouds Future Of Avanir’s Alzheimer’s Agitation Candidate

Otsuka’s Avanir hit by failed second trial in Phase III program with candidate for agitation associated with Alzheimer’s, prompting a re-think of development plans and potentially helping rivals in a high-need indication.

 

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Axsome Therapeutics Inc.
  • Senior Management
  • Herriot Tabuteau, MD, CEO
    Nick Pizzie, CFO
    Cedric O’Gorman, MD, SVP, Clin. Dev. & Medical Affairs
    David Marek, Chief Commercial Officer
  • Contact Info
  • Axsome Therapeutics Inc.
    Phone: (212) 332-3241
    200 Broadway
    3rd Fl.
    New York, NY 10038
    USA
UsernamePublicRestriction

Register